Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

FATEFATE THERAPEUTICS INC

Nasdaq · CIK 0001434316
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts312

Identity from submissions API

NameFATE THERAPEUTICS INC
CIK0001434316
TickersFATE
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN651311552
LEI—
Fiscal year end1231
State of incorporation—
Phone858.875.1803
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
CA
Mailing address
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

858 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-12 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-003536 333-299862 261548841 33 1708
2026-11-12 424B5 424B5 0001193125-26-458736 333-299862 261548171 33 379878
2026-11-09 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0000905148-26-004718 005-87649 261537458 34 31965
2026-11-05 S-3 S-3 0001193125-26-450034 333-299862 261528117 33 649206 1 1
2026-11-05 424B5 424B5 0001193125-26-450013 333-275402 261528023 33 388826
2026-11-05 8-K 8-K 1.01,1.02,9.01 0001193125-26-449840 001-36076 261527424 34 451182 1 1
2026-11-05 10-Q 10-Q 0001193125-26-448543 001-36076 261524726 34 12930970 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-448530 001-36076 261524694 34 450738 1 1
2026-11-04 4 4 0001193125-26-447171 5474
2026-11-03 144 xsl144X01/primary_doc.xml 0001959173-26-007696 001-36076 261516963 33 4389
2026-09-28 8-K 8-K 8.01,9.01 0001193125-26-403429 001-36076 261412022 34 177935 1 1
2026-08-13 S-8 S-8 0001193125-26-349151 333-298302 261273229 33 187300 1 1
2026-08-13 10-Q 10-Q 0001193125-26-347988 001-36076 261270211 34 11539167 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001193125-26-347984 001-36076 261270205 34 435637 1 1
2026-08-05 4 4 0001193125-26-335019 5523
2026-08-05 4 4 0001193125-26-335007 5500
2026-08-04 144 xsl144X01/primary_doc.xml 0001959173-26-005627 001-36076 261239533 33 4999
2026-08-04 144 xsl144X01/primary_doc.xml 0001959173-26-005625 001-36076 261239421 33 5079
2026-07-08 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-001939 005-87649 261161290 34 10799
2026-06-15 4 OWNERSHIP DOCUMENT 0001104659-26-074130 9334
2026-06-15 4 OWNERSHIP DOCUMENT 0001104659-26-074126 7455
2026-06-15 4 4 0001193125-26-271090 5771
2026-06-15 4 4 0001193125-26-271088 5762
2026-06-15 4 4 0001193125-26-271083 5778
2026-06-15 4 4 0001193125-26-271079 5770
2026-06-15 4 4 0001193125-26-271074 5767
2026-06-15 4 4 0001193125-26-271072 5732
2026-06-15 4 4 0001193125-26-271069 5711
2026-06-15 3 3 0001193125-26-271062 11623
2026-06-15 8-K 8-K 5.02,5.07,9.01 0001193125-26-271055 001-36076 261090711 34 784647 1 1
2026-06-04 8-K 8-K 8.01,9.01 0001193125-26-257558 001-36076 261065574 34 15332674 1 1
2026-05-21 4 4 0001193125-26-234390 5599
2026-05-21 4 4 0001193125-26-234380 5576
2026-05-20 144 xsl144X01/primary_doc.xml 0001959173-26-003833 001-36076 261003711 33 4481
2026-05-20 144 xsl144X01/primary_doc.xml 0001959173-26-003832 001-36076 261003701 33 4408
2026-05-13 10-Q 10-Q 0001193125-26-220696 001-36076 26971083 34 9954195 1 1
2026-05-13 8-K 8-K 2.02,9.01 0001193125-26-220691 001-36076 26971065 34 378405 1 1
2026-05-07 4 4 0001193125-26-211820 10661
2026-05-06 4 4 0001193125-26-208899 6690
2026-05-06 4 4 0001193125-26-208891 8559
2026-04-24 ARS ARS 0001193125-26-177241 001-36076 26893842 34 4409006
2026-04-24 DEFA14A DEFA14A 0001193125-26-177171 001-36076 26893724 34 135787
2026-04-24 DEF 14A DEF 14A 0001193125-26-177094 001-36076 26893509 34 2781196 1 1
2026-04-23 4/A OWNERSHIP DOCUMENT 0001104659-26-047974 15692
2026-04-22 4 OWNERSHIP DOCUMENT 0001104659-26-047072 31191
2026-04-22 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001104659-26-047066 005-87649 26885318 34 28045
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001228 005-87649 26800047 34 7138
2026-02-26 10-K 10-K 0001193125-26-073699 001-36076 26682010 34 19766374 1 1
2026-02-26 8-K 8-K 2.02,9.01 0001193125-26-073689 001-36076 26681994 34 435152 1 1
2026-01-16 4 4 0001193125-26-015328 7270
2026-01-16 4 4 0001193125-26-015323 7216
2026-01-16 4 4 0001193125-26-015294 7250
2026-01-12 4 4 0001193125-26-010356 5487
2026-01-12 4 4 0001193125-26-010352 5363
2026-01-09 144 xsl144X01/primary_doc.xml 0001959173-26-000240 001-36076 26522765 33 4407
2026-01-09 144 xsl144X01/primary_doc.xml 0001959173-26-000239 001-36076 26522762 33 4484
2025-12-29 144 xsl144X01/primary_doc.xml 0001959173-25-007928 001-36076 251608425 33 5329
2025-11-13 10-Q 10-Q 0001193125-25-279096 001-36076 251475610 34 12824064 1 1
2025-11-13 8-K 8-K 2.02,9.01 0001193125-25-279091 001-36076 251475605 34 473432 1 1
2025-10-27 8-K 8-K 7.01,8.01,9.01 0001193125-25-250674 001-36076 251417419 34 189470 1 1
2025-10-21 4 4 0001193125-25-245106 7054
2025-10-21 3 3 0001193125-25-245098 14454
2025-10-20 S-8 S-8 0001193125-25-243708 333-290972 251404464 33 197069 1 1
2025-10-14 8-K 8-K 5.02,7.01,9.01 0001193125-25-238989 001-36076 251391711 34 279928 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193805-25-001193 005-87649 251219889 34 8262
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000769993-25-000505 005-87649 251215863 34 17037
2025-08-12 10-Q 10-Q 0000950170-25-107309 001-36076 251206752 34 12234043 1 1
2025-08-12 8-K 8-K 2.02,2.05,9.01 0001193125-25-178947 001-36076 251206679 34 239883 1 1
2025-08-05 4 4 0000950170-25-102983 5385
2025-08-05 4 4 0000950170-25-102979 5361
2025-08-04 144 xsl144X01/primary_doc.xml 0001959173-25-004933 001-36076 251181215 33 4405
2025-08-04 144 xsl144X01/primary_doc.xml 0001959173-25-004926 001-36076 251180506 33 4485
2025-07-29 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000879 005-87649 251159910 34 6176
2025-07-03 3 OWNERSHIP DOCUMENT 0001104659-25-065775 11533
2025-07-03 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-25-065772 005-87649 251105496 34 22235
2025-06-17 8-K/A 8-K/A 5.07 0001193125-25-142037 001-36076 251053237 34 140475 1 1
2025-06-04 S-8 S-8 0001193125-25-134875 333-287765 251023053 33 67800
2025-05-30 4 OWNERSHIP DOCUMENT 0001104659-25-055046 7352
2025-05-30 4 OWNERSHIP DOCUMENT 0001104659-25-055045 9124
2025-05-30 8-K 8-K 5.02,5.03,5.07,7.01,9.01 0001193125-25-132301 001-36076 251012208 34 558834 1 1
2025-05-30 4 4 0000950170-25-079720 14947
2025-05-30 4 4 0000950170-25-079719 14994
2025-05-30 4 4 0000950170-25-079717 14934
2025-05-30 4 4 0000950170-25-079716 14819
2025-05-30 4 4 0000950170-25-079715 14951
2025-05-30 4 4 0000950170-25-079712 14979
2025-05-30 4 4 0000950170-25-079711 5294
2025-05-30 4 4 0000950170-25-079710 14934
2025-05-30 3 3 0000950170-25-079682 14312
2025-05-15 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001193805-25-000667 005-87649 25954128 34 8155
2025-05-13 10-Q 10-Q 0000950170-25-070285 001-36076 25939892 34 10373058 1 1
2025-05-13 8-K 8-K 2.02,9.01 0000950170-25-070280 001-36076 25939847 34 406436 1 1
2025-05-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000769993-25-000238 005-87649 25929228 34 16374
2025-04-23 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001497 005-87649 25863234 34 10815
2025-04-17 ARS ARS 0001193125-25-084322 001-36076 25847386 34 1627106
2025-04-17 DEFA14A DEFA14A 0001193125-25-084316 001-36076 25847338 34 137112
2025-04-17 DEF 14A DEF 14A 0001193125-25-084310 001-36076 25847282 34 2674266 1 1
2025-04-07 PRE 14A PRE 14A 0001193125-25-074632 001-36076 25818083 34 2690430 1 1
2025-03-06 144 xsl144X01/primary_doc.xml 0001959173-25-001767 001-36076 25714600 33 5915
2025-03-05 10-K 10-K 0000950170-25-033510 001-36076 25710824 34 17521572 1 1
2025-03-05 8-K 8-K 2.02,9.01 0000950170-25-033507 001-36076 25710813 34 461798 1 1
2025-01-16 4 4 0000950170-25-006318 5377
2025-01-16 4 4 0000950170-25-006311 7174
2025-01-16 4 4 0000950170-25-006310 7194
2025-01-13 4 4 0000950170-25-004825 5514
2025-01-13 4 4 0000950170-25-004823 5495
2025-01-13 4 4 0000950170-25-004814 5455
2025-01-10 144 xsl144X01/primary_doc.xml 0001959173-25-000245 001-36076 25522574 33 4492
2025-01-10 144 xsl144X01/primary_doc.xml 0001959173-25-000242 001-36076 25522540 33 4438
2025-01-10 144 xsl144X01/primary_doc.xml 0001959173-25-000241 001-36076 25522539 33 4414
2025-01-06 8-K 8-K 5.02,9.01 0001193125-25-002153 001-36076 25510975 34 218957 1 1
2024-12-26 4 OWNERSHIP DOCUMENT 0001104659-24-131794 24324
2024-12-26 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-24-131793 005-87649 241582070 34 26822
2024-12-20 144 xsl144X01/primary_doc.xml 0001104659-24-130954 001-36076 241569501 33 6123
2024-12-16 4 OWNERSHIP DOCUMENT 0001104659-24-129070 12409
2024-11-29 8-K 8-K 5.02,7.01,9.01 0001193125-24-268003 001-36076 241515974 34 175005 1 1
2024-11-14 SC 13G/A FATE THERAPEUTICS, INC. 0000902664-24-006648 005-87649 241465301 34 74580
2024-11-12 10-Q 10-Q 0000950170-24-125317 001-36076 241447866 34 10659291 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-125307 001-36076 241447800 34 406940 1 1
2024-11-08 SC 13G/A us31189p1021_110824.txt 0002012383-24-004004 005-87649 241442018 34 13810
2024-10-25 SC 13G/A ff4031858_13ga1-fate.htm 0000895345-24-000479 005-87649 241398237 34 220162
2024-10-21 SC 13G/A us31189p1021_102124.txt 0002012383-24-000958 005-87649 241383579 34 13798
2024-08-30 8-K 8-K 1.01,5.02,9.01 0001193125-24-211130 001-36076 241270391 34 250772 1 1
2024-08-21 3 3 0000950170-24-099503 19578
2024-08-13 10-Q 10-Q 0000950170-24-096187 001-36076 241201445 34 10128297 1 1
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-096177 001-36076 241201403 34 401216 1 1
2024-08-07 4 4 0000950170-24-092718 4532
2024-08-06 144 xsl144X01/primary_doc.xml 0001959173-24-005350 001-36076 241177762 33 4365
2024-07-31 4 4 0000950170-24-088775 5386
2024-07-31 4 4 0000950170-24-088770 5203
2024-07-31 4 4 0000950170-24-088769 5421
2024-07-31 3 3 0000950170-24-088766 12975
2024-07-31 8-K 8-K 5.02,7.01,9.01 0001193125-24-189911 001-36076 241161847 34 174891 1 1
2024-06-11 4 OWNERSHIP DOCUMENT 0001104659-24-070507 7351
2024-06-11 4 OWNERSHIP DOCUMENT 0001104659-24-070506 9120
2024-06-11 4 4 0000950170-24-071970 5604
2024-06-11 4 4 0000950170-24-071959 5639
2024-06-11 4 4 0000950170-24-071950 5695
2024-06-11 4 4 0000950170-24-071948 5615
2024-06-11 4 4 0000950170-24-071947 5643
2024-06-11 4 4 0000950170-24-071945 5498
2024-06-11 4 4 0000950170-24-071941 5491
2024-06-10 S-8 S-8 0001193125-24-158427 333-280097 241033672 33 67835
2024-06-10 8-K 8-K 5.03,9.01 0001193125-24-158374 001-36076 241033201 34 157236 1 1
2024-06-07 8-K 8-K 5.02,5.07,9.01 0001193125-24-157554 001-36076 241030771 34 273930 1 1
2024-05-31 8-K 8-K 5.02 0001193125-24-151963 001-36076 241010852 34 141950 1 1
2024-05-09 10-Q 10-Q 0000950170-24-056869 001-36076 24930399 34 9039414 1 1
2024-05-09 8-K 8-K 2.02,9.01 0000950170-24-056852 001-36076 24930331 34 358692 1 1
2024-05-09 8-K 8-K 7.01,8.01,9.01 0001193125-24-134840 001-36076 24928857 34 192706 1 1
2024-05-02 424B3 424B3 0001193125-24-129342 333-278792 24908010 33 289043
2024-04-29 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-29 16:30:00 9999999995-24-001190 333-278792 24893787 33 1714
2024-04-26 ARS ARS 0001193125-24-118086 001-36076 24883996 34 11392982
2024-04-26 DEFA14A DEFA14A 0001193125-24-118056 001-36076 24883794 34 665274
2024-04-26 DEF 14A DEF 14A 0001193125-24-117981 001-36076 24883611 34 3237960 1 1
2024-04-25 CORRESP filename1.htm 0001193125-24-113811 10955
2024-04-24 UPLOAD filename1.pdf 0000000000-24-004575 333-278792 40247
2024-04-18 S-3 S-3 0001193125-24-100748 333-278792 24854277 33 395038
2024-04-16 PRE 14A PRE 14A 0001193125-24-097724 001-36076 24847834 34 3254663 1 1
2024-03-25 4 OWNERSHIP DOCUMENT 0001104659-24-038585 9509
2024-03-25 SC 13D/A SC 13D/A 0001104659-24-038492 005-87649 24780144 34 132927
2024-03-21 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-24-072871 001-36076 24768707 34 674136 1 1
2024-03-20 424B5 424B5 0001193125-24-072868 333-275402 24768702 33 566171
2024-03-05 4 4 0000950170-24-025992 4607
2024-03-04 144 xsl144X01/primary_doc.xml 0001959173-24-001754 001-36076 24714141 33 6771
2024-02-26 10-K 10-K 0000950170-24-020158 001-36076 24678816 34 11936677 1 1
2024-02-26 8-K 8-K 2.02,9.01 0000950170-24-020123 001-36076 24678575 34 403380 1 1
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020912 005-87649 24628390 34 13005
2024-02-12 SC 13G ff3013867_13g-fate.htm 0000895345-24-000042 005-87649 24621762 34 198768
2024-02-09 SC 13G/A SEC SCHEDULE 13G 0001422848-24-000230 005-87649 24616806 34 18198
2024-02-02 4 4 0000950170-24-010491 5376
2024-02-02 4 4 0000950170-24-010490 5356
2024-02-02 4 4 0000950170-24-010485 5382
2024-02-02 4 4 0000950170-24-010484 5379
2024-01-30 4 4 0000950170-24-008803 4607
2024-01-29 144 xsl144X01/primary_doc.xml 0001959173-24-000484 001-36076 24572615 33 6172
2024-01-25 SC 13G FATE THERAPEUTICS INC 0000902664-24-000657 005-87649 24562418 34 84938
2024-01-24 SC 13G/A us31189p1021_012324.txt 0001086364-24-002058 005-87649 24554663 34 13479
2024-01-22 SC 13G/A Fate_Therapeutics_Inc.txt 0000093751-24-000067 005-87649 24548053 34 8428
2024-01-10 4 4 0000950170-24-003652 5536
2024-01-10 4 4 0000950170-24-003650 5559
2024-01-10 4 4 0000950170-24-003648 5459
2024-01-10 4 4 0000950170-24-003647 5464
2024-01-09 144 xsl144X01/primary_doc.xml 0001959173-24-000227 001-36076 24523716 33 4436
2024-01-09 144 xsl144X01/primary_doc.xml 0001959173-24-000225 001-36076 24523704 33 5476
2024-01-09 144 xsl144X01/primary_doc.xml 0001959173-24-000224 001-36076 24523700 33 4849
2024-01-09 144 xsl144X01/primary_doc.xml 0001959173-24-000223 001-36076 24523692 33 4279
2024-01-03 4 4 0000950170-24-000874 4607
2024-01-02 144 xsl144X01/primary_doc.xml 0001959173-24-000021 001-36076 24501263 33 5528
2023-12-28 4 OWNERSHIP DOCUMENT 0001104659-23-130203 11431
2023-12-28 SC 13D/A SC 13D/A 0001104659-23-130098 005-87649 231523276 34 75308
2023-12-19 4 FORM 4 SUBMISSION 0001209191-23-059103 4837
2023-12-18 144 xsl144X01/primary_doc.xml 0001959173-23-005567 001-36076 231492677 33 4386
2023-11-27 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-11-27 16:30:00 9999999995-23-003442 333-275402 231441760 33 1666
2023-11-21 CORRESP filename1.htm 0001193125-23-281480 9944
2023-11-15 UPLOAD filename1.pdf 0000000000-23-012533 40284
2023-11-13 4 FORM 4 SUBMISSION 0001209191-23-054968 4730
2023-11-09 144 xsl144X01/primary_doc.xml 0001959173-23-004622 001-36076 231391264 33 5898
2023-11-08 8-K 8-K 1.01,1.02,9.01 0001193125-23-273633 001-36076 231389194 34 151465 1 1
2023-11-08 S-3 S-3 0001193125-23-273593 333-275402 231388865 33 786664
2023-11-08 10-Q 10-Q 0000950170-23-061080 001-36076 231387759 34 12768949 1 1
2023-11-08 8-K 8-K 2.02,9.01 0000950170-23-061077 001-36076 231387709 34 458021 1 1
2023-10-10 SC 13G/A Fate_Therapeutics_Inc.txt 0000093751-23-000682 005-87649 231316619 34 8374
2023-09-01 8-K 8-K 8.01 0001193125-23-227749 001-36076 231233495 34 144816 1 1
2023-08-21 4 FORM 4 SUBMISSION 0001209191-23-046691 5501
2023-08-18 144 xsl144X01/primary_doc.xml 0001959173-23-003379 001-36076 231185767 33 4802
2023-08-08 10-Q 10-Q 0000950170-23-039803 001-36076 231151358 34 13705947 1 1
2023-08-08 8-K 8-K 2.02,9.01 0000950170-23-039783 001-36076 231151258 34 496335 1 1
2023-08-07 4 FORM 4 SUBMISSION 0001209191-23-044768 4682
2023-08-04 144 xsl144X01/primary_doc.xml 0001959173-23-002912 001-36076 231142603 33 4868
2023-07-06 4 FORM 4 SUBMISSION 0001209191-23-041611 5482
2023-07-06 4 FORM 4 SUBMISSION 0001209191-23-041607 4755
2023-07-05 144 xsl144X01/primary_doc.xml 0001959173-23-002242 001-36076 231068245 33 4174
2023-07-05 144 xsl144X01/primary_doc.xml 0001959173-23-002236 001-36076 231067509 33 4844
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037302 4683
2023-06-14 144 xsl144X01/primary_doc.xml 0001959173-23-001856 001-36076 231013372 33 4287
2023-06-09 8-K 8-K 5.07 0000950170-23-027262 001-36076 231005315 34 215665 1 1
2023-06-08 4 OWNERSHIP DOCUMENT 0001104659-23-069540 8985
2023-06-08 4 OWNERSHIP DOCUMENT 0001104659-23-069538 7246
2023-06-08 8-K 8-K 5.02 0000950170-23-027007 001-36076 231002037 34 160687 1 1
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035066 5788
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035062 5749
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035059 5636
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035055 5784
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035051 5737
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035049 5643
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035044 5840
2023-06-07 4 FORM 4 SUBMISSION 0001209191-23-035039 5760
2023-06-07 8-K 8-K 8.01 0000950170-23-026747 001-36076 23997764 34 171024 1 1
2023-05-10 SC 13G/A FATE_THERAPEUTICS_INC.txt 0000093751-23-000560 005-87649 23904593 34 10283
2023-05-03 10-Q 10-Q 0000950170-23-017175 001-36076 23883790 34 11840725 1 1
2023-05-03 8-K 8-K 2.02,9.01 0000950170-23-017157 001-36076 23883682 34 444727 1 1
2023-04-21 4 OWNERSHIP DOCUMENT 0001104659-23-048557 10114
2023-04-21 ARS ARS 0001193125-23-110500 001-36076 23836434 34 2750513
2023-04-21 DEFA14A DEFA14A 0001193125-23-110484 001-36076 23836368 34 36850
2023-04-21 DEF 14A DEF 14A 0001193125-23-110475 001-36076 23836304 34 2706138 1 1
2023-04-19 SC 13D/A SC 13D/A 0001104659-23-047252 005-87649 23830770 34 93562
2023-04-19 4 FORM 4 SUBMISSION 0001209191-23-024820 7215
2023-04-19 8-K 8-K 3.01,5.03,9.01 0000950170-23-013471 001-36076 23830097 34 192367 1 1
2023-04-18 144 xsl144X01/primary_doc.xml 0001959173-23-000617 001-36076 23826690 33 4174
2023-04-17 4 OWNERSHIP DOCUMENT 0001104659-23-046353 36101
2023-04-14 144 xsl144X01/primary_doc.xml 0001104659-23-045209 001-36076 23819621 33 11779
2023-03-22 SC 13G FATE_SC13G.htm 0001273087-23-000102 005-87649 23753103 34 81948
2023-03-10 SC 13G/A SCHEDULE 13G/A 0001104659-23-030867 005-87649 23721643 34 12925
2023-02-28 10-K 10-K 0000950170-23-005067 001-36076 23685158 34 16381768 1 1
2023-02-28 8-K 8-K 2.02,9.01 0000950170-23-005063 001-36076 23685064 34 526195 1 1
2023-02-13 SC 13G SEC SCHEDULE 13G 0001422849-23-000056 005-87649 23617326 34 18163
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015938 005-87649 23603192 34 12926
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007513 5494
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007511 5496
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007509 5473
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007507 5486
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007503 5499
2023-02-07 4 FORM 4 SUBMISSION 0001209191-23-007497 5483
2023-02-03 SC 13G Fate_Therapeutics_Inc.txt 0000093751-23-000111 005-87649 23584053 34 8412
2023-01-20 4 FORM 4 SUBMISSION 0001209191-23-004237 6605
2023-01-13 4 FORM 4 SUBMISSION 0001209191-23-003338 5823
2023-01-13 4 FORM 4 SUBMISSION 0001209191-23-003261 6800
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002979 5673
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002978 5673
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002977 5650
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002976 5486
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002975 5578
2023-01-11 4 FORM 4 SUBMISSION 0001209191-23-002974 5659
2023-01-06 SC 13G/A us31189p1021_010523.txt 0001306550-23-000063 005-87649 23514318 34 13365
2023-01-05 8-K 8-K 1.02,2.05,5.02,8.01,9.01 0001193125-23-002504 001-36076 23512341 34 201704 1 1
2022-11-07 8-K 8-K 1.01,7.01,9.01 0000950170-22-022488 001-36076 221364675 34 262355 1 1
2022-11-03 10-Q 10-Q 0000950170-22-021840 001-36076 221357893 34 14664023 1 1
2022-11-03 8-K 8-K 2.02,9.01 0000950170-22-021834 001-36076 221357844 34 570005 1 1
2022-08-19 4 FORM 4 SUBMISSION 0001209191-22-046929 7040
2022-08-03 10-Q 10-Q 0000950170-22-014236 001-36076 221132613 34 13137485 1 1
2022-08-03 8-K 8-K 2.02,9.01 0000950170-22-014223 001-36076 221132481 34 547798 1 1
2022-07-25 4 FORM 4 SUBMISSION 0001209191-22-043143 19783
2022-07-08 4 FORM 4 SUBMISSION 0001209191-22-041670 9018
2022-07-07 4 FORM 4 SUBMISSION 0001209191-22-041440 12783
2022-07-06 4 FORM 4 SUBMISSION 0001209191-22-041053 5484
2022-06-30 8-K 8-K 1.01,7.01,9.01 0000950170-22-012381 001-36076 221058093 34 225166 1 1
2022-06-29 4 FORM 4 SUBMISSION 0001209191-22-039819 7413
2022-06-29 3 FORM 3 SUBMISSION 0001209191-22-039817 6904
2022-06-13 4 OWNERSHIP DOCUMENT 0001104659-22-070681 11148
2022-06-13 4 OWNERSHIP DOCUMENT 0001104659-22-070679 9194
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036355 7289
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036353 9165
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036350 7138
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036349 7284
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036347 7238
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036345 7144
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036343 8628
2022-06-13 4 FORM 4 SUBMISSION 0001209191-22-036338 7261
2022-06-13 8-K 8-K 5.02,5.07,9.01 0000950170-22-011554 001-36076 221011699 34 212108 1 1
2022-06-09 S-8 S-8 0001193125-22-171100 333-265502 221006445 33 376294
2022-06-08 4 FORM 4 SUBMISSION 0001209191-22-034996 5345
2022-06-08 4/A FORM 4/A SUBMISSION 0001209191-22-034992 4793
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034554 5223
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034551 5369
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034546 5321
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034541 5426
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034536 5344
2022-06-02 4 FORM 4 SUBMISSION 0001209191-22-033481 8585
2022-05-04 10-Q 10-Q 0000950170-22-007389 001-36076 22891711 34 11383239 1 1
2022-05-04 8-K 8-K 2.02,9.01 0000950170-22-007377 001-36076 22891506 34 469600 1 1
2022-04-25 4 FORM 4 SUBMISSION 0001209191-22-025515 21485
2022-04-25 DEFA14A DEFA14A 0001193125-22-117538 001-36076 22849758 34 60185
2022-04-25 DEF 14A DEF 14A 0001193125-22-117516 001-36076 22849680 34 1371173
2022-04-21 4 FORM 4 SUBMISSION 0001209191-22-025159 5458
2022-04-04 4 FORM 4 SUBMISSION 0001209191-22-022495 12375
2022-03-15 4 FORM 4 SUBMISSION 0001209191-22-018820 15801
2022-03-11 4 FORM 4 SUBMISSION 0001209191-22-018188 10540
2022-02-28 S-8 S-8 0001193125-22-058233 333-263102 22691345 33 89563
2022-02-28 10-K 10-K 0000950170-22-002293 001-36076 22689661 34 15700082 1 1
2022-02-28 8-K 8-K 2.02,9.01 0000950170-22-002285 001-36076 22689336 34 523790 1 1
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-017527 005-87649 22609722 34 12921
2022-02-09 SC 13G/A SC 13G/A 0001104659-22-016155 005-87649 22605911 34 40423
2022-02-04 4/A FORM 4/A SUBMISSION 0000899243-22-004871 10096
2022-02-03 SC 13G/A us31189p1021_020222.txt 0000834237-22-005412 005-87649 22585630 34 13364
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003449 7403
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003448 7360
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003447 7368
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003443 7376
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003426 5457
2022-01-27 4 FORM 4 SUBMISSION 0000899243-22-003424 7364
2022-01-27 4/A FORM 4/A SUBMISSION 0000899243-22-003421 5903
2022-01-24 4 FORM 4 SUBMISSION 0001209191-22-004606 13941
2022-01-13 4 FORM 4 SUBMISSION 0001209191-22-003174 7327
2022-01-13 4 FORM 4 SUBMISSION 0001209191-22-003172 7323
2022-01-13 4 FORM 4 SUBMISSION 0001209191-22-003170 7325
2022-01-13 4 FORM 4 SUBMISSION 0001209191-22-003168 7232
2022-01-13 4 FORM 4 SUBMISSION 0001209191-22-003166 7324
2022-01-12 4 FORM 4 SUBMISSION 0001209191-22-003054 8789
2022-01-12 4 FORM 4 SUBMISSION 0001209191-22-003051 7230
2022-01-12 4 FORM 4 SUBMISSION 0001209191-22-003047 7232
2022-01-04 4 FORM 4 SUBMISSION 0001209191-22-000647 14247
2021-12-21 4 FORM 4 SUBMISSION 0001209191-21-070768 8815
2021-12-14 8-K 8-K 8.01,9.01 0001193125-21-356947 001-36076 211492083 34 348861 1 1
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069415 15974
2021-12-13 4 FORM 4 SUBMISSION 0001209191-21-069313 19510
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066168 10619
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066165 5016
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066163 5014
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066162 5013
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066159 5019
2021-11-22 4 FORM 4 SUBMISSION 0001209191-21-066156 5012
2021-11-04 8-K 8-K 1.01,1.02,9.01 0001193125-21-320325 001-36076 211380927 34 408433 1 1
2021-11-04 S-3ASR S-3ASR 0001193125-21-320314 333-260772 211380887 33 992833
2021-11-04 10-Q 10-Q 0000950170-21-003066 001-36076 211380095 34 12510064 1 1
2021-11-04 8-K 8-K 2.02,9.01 0000950170-21-003055 001-36076 211379948 34 543896 1 1
2021-10-25 4 FORM 4 SUBMISSION 0001209191-21-061485 24091
2021-10-12 SC 13G/A filing.txt 0000315066-21-001805 005-87649 211317256 34 8449
2021-10-04 4 FORM 4 SUBMISSION 0001209191-21-058930 12509
2021-09-30 4 FORM 4 SUBMISSION 0001209191-21-058176 8810
2021-09-14 4 FORM 4 SUBMISSION 0001209191-21-055867 12503
2021-09-10 SC 13G SC 13G 0001104659-21-114595 005-87649 211246822 34 43306
2021-08-20 4 FORM 4 SUBMISSION 0001209191-21-052744 8606
2021-08-20 4 FORM 4 SUBMISSION 0001209191-21-052742 9233
2021-08-05 4 FORM 4 SUBMISSION 0001209191-21-049914 7309
2021-08-05 3 FORM 3 SUBMISSION 0001209191-21-049911 6863
2021-08-04 10-Q 10-Q 0001564590-21-040821 001-36076 211144173 34 11295813 1 1
2021-08-04 8-K 8-K 2.02,9.01 0001564590-21-040793 001-36076 211143987 34 517418 1 1
2021-08-04 8-K 8-K 5.02,7.01,9.01 0001193125-21-235830 001-36076 211142557 34 178629 1 1
2021-07-26 4 FORM 4 SUBMISSION 0000899243-21-029868 22045
2021-07-02 4 FORM 4 SUBMISSION 0001209191-21-045182 37506
2021-06-22 4 FORM 4 SUBMISSION 0001209191-21-042373 11291
2021-06-22 3 FORM 3 SUBMISSION 0001209191-21-042370 6955
2021-06-16 4 FORM 4 SUBMISSION 0001209191-21-040914 16360
2021-06-07 8-K 8-K 5.03,5.07,9.01 0001193125-21-184402 001-36076 211000090 34 173630 1 1
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022091 7320
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022090 7423
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022086 9248
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022085 7225
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022081 7367
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022080 7343
2021-06-04 4 FORM 4 SUBMISSION 0000899243-21-022076 7221
2021-06-04 4 OWNERSHIP DOCUMENT 0001104659-21-077005 11235
2021-06-04 4 OWNERSHIP DOCUMENT 0001104659-21-077002 9288
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035301 8749
2021-05-05 10-Q 10-Q 0001564590-21-024037 001-36076 21893247 34 9632027 1 1
2021-05-05 8-K 8-K 2.02,9.01 0001564590-21-024017 001-36076 21893086 34 445803 1 1
2021-04-26 4 FORM 4 SUBMISSION 0001209191-21-028259 21635
2021-04-21 DEFA14A DEFA14A 0001193125-21-124711 001-36076 21841688 34 868584
2021-04-21 DEF 14A DEF 14A 0001193125-21-124699 001-36076 21841665 34 921391
2021-04-20 4 FORM 4 SUBMISSION 0001209191-21-027545 9850
2021-04-07 PRE 14A PRE 14A 0001193125-21-108952 001-36076 21812685 34 921384
2021-04-02 4 FORM 4 SUBMISSION 0000899243-21-014635 25561
2021-04-02 3 FORM 3 SUBMISSION 0000899243-21-014594 11571
2021-04-02 4/A FORM 4/A SUBMISSION 0000899243-21-014588 7596
2021-03-25 8-K 8-K 5.02,9.01 0001564590-21-015473 001-36076 21772276 34 208670 1 1
2021-03-16 4 FORM 4 SUBMISSION 0000899243-21-011920 16112
2021-03-09 4 FORM 4 SUBMISSION 0001209191-21-018932 18361
2021-02-24 S-8 S-8 0001564590-21-008148 333-253459 21674186 33 218761
2021-02-24 10-K 10-K 0001564590-21-008086 001-36076 21673181 34 16569070 1 1
2021-02-24 8-K 8-K 2.02,9.01 0001564590-21-008069 001-36076 21672955 34 516645 1 1
2021-02-19 4 FORM 4 SUBMISSION 0001209191-21-012326 16874
2021-02-10 SC 13G SCHEDULE 13G 0001104659-21-018063 005-87649 21610692 34 13844
2021-02-08 SC 13G/A filing.txt 0000315066-21-000992 005-87649 21599526 34 8392
2021-02-03 SC 13G/A fatetherapeutics13ga1_123120.htm 0001040188-21-000052 005-87649 21585248 34 40638
2021-02-03 SC 13G/A fatetherapeutics13ga1_123120.htm 0001040188-21-000055 005-87649 21584837 34 40638
2021-01-29 SC 13G/A us31189p1021_012921.txt 0000834237-21-003910 005-87649 21568821 34 13456
2021-01-22 4 FORM 4 SUBMISSION 0001209191-21-004957 42189
2021-01-22 4 FORM 4 SUBMISSION 0001209191-21-004956 7371
2021-01-22 4 FORM 4 SUBMISSION 0001209191-21-004955 7340
2021-01-22 4 FORM 4 SUBMISSION 0001209191-21-004954 7373

Latest XBRL company facts

One latest value per concept from companyfacts (312 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 121.57M 2026-10-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
dei EntityPublicFloat Entity Public Float USD 113.00M 2025-06-30 2025 FY 10-K 2026-02-26 0001193125-26-073699
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 574,491 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001193125-26-177094
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 913,398 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001193125-26-177094
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 9.71 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001193125-26-177094
ffd NetFeeAmt NetFeeAmt USD 26,100 2026-11-05 S-3 2026-11-05 0001193125-26-450034
ffd TtlFeeAmt TtlFeeAmt USD 26,100 2026-11-05 S-3 2026-11-05 0001193125-26-450034
ffd TtlOfferingAmt TtlOfferingAmt USD 300.00M 2026-11-05 S-3 2026-11-05 0001193125-26-450034
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-05 S-3 2026-11-05 0001193125-26-450034
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-05 S-3 2026-11-05 0001193125-26-450034
us-gaap AccountsPayableAndAccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Current USD 3.73M 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap AccountsPayableAndAccruedLiabilitiesNoncurrent Accounts Payable and Accrued Liabilities, Noncurrent USD 549,000 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 479,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 2.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 15.15M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 7.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 36.22M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -155,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.76B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 248.96M 2016-12-31 2016 FY 10-K 2017-03-16 0001564590-17-004614
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.70M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 0 2025-01-01 2025-03-31 2025 Q1 10-Q 2025-05-13 0000950170-25-070285
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 217,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 10.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 24,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 115,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 36.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap Assets Assets USD 238.28M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AssetsCurrent Assets, Current USD 144.26M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 2,000 2018-12-31 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 53.18M 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 55.72M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 51,000 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 13,000 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 55.73M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 53.23M 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 37,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CapitalizedContractCostAmortization Capitalized Contract Cost, Amortization USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-05 0000950170-25-033510
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 43.94M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -48.00M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-15 0001564590-17-011043
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 139.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 36.39M 2018-06-30 2018 Q2 10-Q 2018-08-06 0001564590-18-019456
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 49.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -7.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 100 2023-11-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 230,000 2013-10-04 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 50.61M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 350.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 121.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 121.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap CommonStockValue Common Stock, Value, Issued USD 122,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest USD -92.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ContractsRevenue Contracts Revenue (Deprecated 2018-01-31) USD 1.03M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap ContractualObligation Contractual Obligation USD 59.70M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueAfterFifthYear Contractual Obligation, to be Paid, after Year Five USD 22.47M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueInFifthYear Contractual Obligation, to be Paid, Year Five USD 4.11M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueInFourthYear Contractual Obligation, to be Paid, Year Four USD 5.62M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueInNextTwelveMonths Contractual Obligation, to be Paid, Year One USD 6.74M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueInSecondYear Contractual Obligation, to be Paid, Year Two USD 10.58M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractualObligationDueInThirdYear Contractual Obligation, to be Paid, Year Three USD 10.19M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap ContractWithCustomerAssetNetNoncurrent Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005067
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 56.53M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 20.00M 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap ConvertibleNotesPayable Convertible Notes Payable USD 23.70M 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 3.48M 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 7.23M 2013-09-13 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 22.08M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount USD 22.10M 2013-10-04 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 15.00M 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 336,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 15.00M 2017-07-14 2020 Q1 10-Q 2020-05-11 0001564590-20-024213
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD -371,000 2014-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 268.11M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061080
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 499,000 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061080
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 11.36M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 12,000 2017-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 3.40M 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap DeferredRevenue Deferred Revenue USD 5.46M 2015-09-30 2015 Q3 10-Q 2015-11-03 0001104659-15-075283
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 2.10M 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 198,000 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 2.30M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 8.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 399.33M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsNetNoncurrent Deferred Tax Assets, Net of Valuation Allowance, Noncurrent USD 0 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 186.85M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 36,000 2014-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.03M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 1.65M 2019-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 66.65M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 6.73M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 387.97M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 387.97M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD -1.11M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 600,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005067
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 8.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 93.49M 2014-03-31 2014 Q1 10-Q 2014-05-13 0001104659-14-038138
us-gaap Dividends Dividends USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005067
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.76 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.68 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007389
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.76 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.186 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.076 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.022 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 1.23M 2014-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 31.00M 2024-06-30 2024 Q2 10-Q 2024-08-13 0000950170-24-096187
us-gaap EquityIssuancePerShareAmount Development Stage Entities, Equity Issuance, Per Share Amount (Deprecated 2015-01-31) USD 6 2013-10-04 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap ExtinguishmentOfDebtGainLossNetOfTax Extinguishment of Debt, Gain (Loss), Net of Tax USD 3,000 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-12 0001104659-14-079407
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 8,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007389
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007389
us-gaap FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Change in Unrealized Gain (Loss) (Deprecated 2019-01-31) USD -2.42M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap FairValueLiabilitiesLevel1ToLevel2TransfersAmount Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap FairValueLiabilitiesLevel2ToLevel1TransfersAmount Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap FinancingReceivableNonaccrualNoAllowance Financing Receivable, Nonaccrual, No Allowance USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -18,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -118,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 26.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 1,600 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxExaminationPenaltiesAndInterestExpense Income Tax Examination, Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 2,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 1,600 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 25.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -28.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.89M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 108,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 202,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -10.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 2.95M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD -4.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -437,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -381,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 515,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD 122,000 2007-04-27 2014-03-31 2014 Q1 10-Q 2014-05-13 0001104659-14-038138
us-gaap IncrementalCommonSharesAttributableToCallOptionsAndWarrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants shares 3.00M 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-07 0001564590-16-027939
us-gaap InterestExpense Interest Expense USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap InterestExpenseDebt Interest Expense, Debt USD 1.80M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 2.31M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-05 0001564590-18-004394
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 2.29M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 4.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Investment Income, Net, Amortization of Discount and Premium USD 335,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap InvestmentTaxCredit Investment Tax Credit USD -1.23M 2007-04-27 2014-03-31 2014 Q1 10-Q 2014-05-13 0001104659-14-038138
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 13,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 2.30M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008086
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.08 2019-06-30 2019 Q2 10-Q 2019-08-06 0001564590-19-029333
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 111.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 53.81M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 11.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 11.25M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 10.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 10.60M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 10.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 2.79M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 36.55M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount USD 10.10M 2026-03-31 2026 Q1 10-Q 2026-05-13 0001193125-26-220696
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 238.28M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LiabilitiesCurrent Liabilities, Current USD 32.69M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap LongTermDebt Long-term Debt USD 18.48M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 2.44M 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 3.72M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five USD 1.54M 2017-12-31 2017 FY 10-K 2018-03-05 0001564590-18-004394
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 1.63M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 6.31M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 6.82M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 12.45M 2018-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap LongTermInvestments Long-term Investments USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 9.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 355,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 64.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -43.84M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -82.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -30.80M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001193125-26-220696
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -92.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap NetRentableArea Net Rentable Area sqft 72,000 2024-10-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347988
us-gaap NumberOfReportableSegments Number of Reportable Segments Disbursement 1 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap OperatingExpenses Operating Expenses USD 99.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -96.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingLeaseCost Operating Lease, Cost USD 15.03M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 3.50M 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-11 0001564590-20-024213
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 74.49M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 5.11M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 69.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 40.01M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 41.22M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 3.02M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 4.11M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 3.99M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 3.87M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.76M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 22.47M 2018-12-31 2018 FY 10-K 2019-03-05 0001564590-19-006258
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.085 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 4.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -271,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -38,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent Other Employee-related Liabilities USD 12.90M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061080
us-gaap OtherGeneralAndAdministrativeExpense Other General and Administrative Expense USD 2.00M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 4.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap OtherResearchAndDevelopmentExpense Other Research and Development Expense USD 10.90M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held USD 0 2023-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale USD 0 2020-01-01 2020-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012939
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 373,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008086
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 7,000 2007-04-27 2014-03-31 2014 Q1 10-Q 2014-05-13 0001104659-14-038138
us-gaap PaymentsOfDebtExtinguishmentCosts Payment for Debt Extinguishment or Debt Prepayment Cost USD 88,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 10,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 5.50M 2024-01-01 2024-03-31 2024 Q3 10-Q 2024-11-12 0000950170-24-125317
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 104.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 319,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 106.18M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 2.76M 2024-06-30 2024 Q2 10-Q 2024-08-13 0000950170-24-096187
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 2.76M 2024-06-30 2024 Q2 10-Q 2024-08-13 0000950170-24-096187
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 3,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 4.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 23.74M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 7.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 58.65M 2007-04-27 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 15.00M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 16.73M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 20.00M 2024-01-01 2024-03-31 2025 Q3 10-Q 2025-11-13 0001193125-25-279096
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments Proceeds from Maturities, Prepayments and Calls of Short-term Investments USD 64.05M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040360
us-gaap ProceedsFromRepaymentsOfDebt Proceeds from (Repayments of) Debt USD 7.50M 2017-07-13 2017-07-14 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap ProceedsFromRepurchaseOfEquity Proceeds from (Repurchase of) Equity USD 287,000 2007-04-27 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 170.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 435,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -92.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 93.15M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 48.91M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap RecognitionOfDeferredRevenue Recognition of Deferred Revenue USD -7.91M 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-03 0001104659-15-075283
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 1.68M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 15.00M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0000950170-22-002293
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 73.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 10.05M 2026-06-30 2026 Q2 10-Q 2026-08-13 0001193125-26-347988
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 5.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.6 2023-01-01 2023-01-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap RestructuringCharges Restructuring Charges USD 1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.63B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 3.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap RevenueFromGrants Revenue from Grants (Deprecated 2018-01-31) USD 345,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125317
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 74.50M 2024-01-01 2024-03-31 2024 Q3 10-Q 2024-11-12 0000950170-24-125317
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 1.03M 2017-10-01 2017-12-31 2017 FY 10-K 2018-03-05 0001564590-18-004394
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 2.40M 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 2.00M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap SharePrice Share Price USD/shares 2.12 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061080
us-gaap SharesIssued Shares, Issued shares 2.76M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061080
us-gaap SharesOutstanding Shares, Outstanding shares 96.86M 2022-06-30 2023 Q2 10-Q 2023-08-08 0000950170-23-039803
us-gaap ShortTermInvestments Short-term Investments USD 95.19M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-09 0000950170-24-056869
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 133.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.154 2013-09-12 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares 3.68M 2013-10-03 2013-10-04 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005067
us-gaap StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services shares 37,641 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-16 0001564590-17-004614
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 7.67M 2013-10-03 2013-10-04 2015 Q1 10-Q 2015-05-07 0001104659-15-035555
us-gaap StockIssuedDuringPeriodSharesPurchaseOfAssets Stock Issued During Period, Shares, Purchase of Assets shares 480,763 2013-10-03 2013-10-04 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 0 2022-01-01 2022-12-31 2023 FY 10-K 2024-02-26 0000950170-24-020158
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 56.53M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap StockIssuedDuringPeriodValueIssuedForCash Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) USD 192,000 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-12 0001047469-15-002070
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 6.10M 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008086
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 432.28M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005067
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 23,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD 7,000 2011-01-01 2011-12-31 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap StraightLineRent Straight Line Rent USD -192,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-02-24 0001564590-21-008086
us-gaap StraightLineRentAdjustments Straight Line Rent Adjustments USD 11.84M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap SubleaseIncome Sublease Income USD 273,000 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-09 0000950170-24-056869
us-gaap TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) USD 25.28M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001564590-20-008141
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 56.53M 2012-12-31 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 58.52M 2013-09-30 2013 Q3 10-Q 2013-11-13 0001104659-13-084191
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0.001 2013-12-31 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 68.36M 2013-09-13 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2013-12-31 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 44.97M 2013-09-13 2015 FY 10-K 2016-03-03 0001564590-16-013981
us-gaap TenantImprovements Tenant Improvements USD 2.50M 2024-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 82.41M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 11.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 275,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2024-12-31 2024 FY 10-K 2025-03-05 0000950170-25-033510
us-gaap VariableLeaseCost Variable Lease, Cost USD 3.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-073699
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 184,000 2012-12-31 2013 FY 10-K 2014-03-17 0001047469-14-002516
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 117.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 121.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 96.34M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007389
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 121.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448543
us-gaap WriteOffOfDeferredDebtIssuanceCost Write off of Deferred Debt Issuance Cost USD 30,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-05 0001564590-18-004394

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →